Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2005

01-02-2005 | Original Article

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

Authors: Richard J. Gralla, Fausto Roila, Maurizio Tonato

Published in: Supportive Care in Cancer | Issue 2/2005

Login to get access

Excerpt

Preventing nausea and vomiting continue to be priorities in the treatment of patients receiving cancer chemotherapy or radiation therapy. Over the past 25 years, progressive improvements in antiemetic therapy have occurred. Most recently, newer agents have become available, and several large trials have been published that help define practice approaches for common clinical settings. …
Literature
1.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (1998) Prevention of chemotherapy and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811–19CrossRefPubMed
2.
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994PubMed
Metadata
Title
The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants
Authors
Richard J. Gralla
Fausto Roila
Maurizio Tonato
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 2/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0756-5

Other articles of this Issue 2/2005

Supportive Care in Cancer 2/2005 Go to the issue

Review Article

Antiemetics in children receiving chemotherapy

Review Article

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

Original Article

Anticipatory nausea and vomiting

Forthcoming Meetings

Forthcoming Meetings February 2005

Review Article

Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines

Review Article

Delayed emesis: moderately emetogenic chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits